Orthocell (ASX:OCC) on the Radar: What Could Drive the Next Move in September 2026?

Aditi Sarkar

14 September 2026 12:34 PM AEST

Orthocell (ASX:OCC) on the Radar: What Could Drive the Next Move in September 2026?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Regenerative medicine rarely moves in a straight line from laboratory to commercial revenue, yet Orthocell (ASX:OCC) has spent FY2026 trying to show that transition is underway. The Perth-based company sells collagen-based medical devices for peripheral nerve and dental bone repair, and its push into the United States behind the Remplir nerve wrap has become the central plank of the story. With a Market Capitalisation of roughly A$197 million as at 11 September 2026 and a record quarterly Revenue result behind it, Orthocell sits between clinical-stage hopeful and commercial business.

Latest Development

On 13 July 2026 Orthocell announced record FY2026 results, headlined by record quarterly revenue of A$3.8 million for the June 2026 quarter — a 20 per cent increase on the March 2026 quarter and 36 per cent higher than the prior corresponding quarter. An investor webinar on the result followed on 15 July 2026.

Since then Orthocell lodged an Appendix 4G and corporate governance statement on 31 August 2026, confirmed its Annual General Meeting date on 9 September 2026, and on 11 September 2026 lodged a cleansing notice and an application for Quotation of securities.

Company Overview

Founded in 2010 and listed on the ASX in August 2014, Orthocell is headquartered at Murdoch in Western Australia, where it operates a GMP-certified, TGA-licensed Manufacturing Facility certified to ISO 13485.

The portfolio spans four products. Remplir is a resorbable collagen device supporting repair and protection of peripheral nerves, and Striate+ is a collagen barrier membrane used in guided bone and tissue regeneration in dentistry. OrthoACI treats cartilage defects and OrthoATI addresses tendinopathy; both are cell therapies that are not FDA-approved and are unavailable in the United States, while the collagen device platform holds US FDA clearance. Orthocell says its technologies have been used in more than 75,000 patients globally.

Recent Developments

The US channel has been the focus. Orthocell has recorded Remplir's first surgical use in the United States and secured access to 221 US military and Veterans Affairs medical centres. The device has also been used in 23 surgeries on Ukrainian soldiers.

Offshore, Remplir holds approval in Australia, New Zealand and Singapore, distributed through Device Technologies, and MediTime was appointed Thai distributor after Thai FDA approval in CY2025. Chief executive Paul Anderson presented at a Canaccord Genuity growth conference in Boston on 12 August 2026.

Financial and Operational Position

For the half year to 31 December 2025, Orthocell reported revenue of A$6.2 million, up about 49 per cent, with cash of roughly A$49.4 million and no debt. The June 2026 quarter delivered A$3.8 million of revenue.

The company has never paid a Dividend and remains loss-making. It describes itself as fully funded for US commercialisation and its regulatory programs.

What Investors May Watch Next

The September 2026 quarterly Cash Flow report, due late in October, is the next scheduled read on whether the June quarter's step-up has held.

Beyond that, attention may fall on conversion of military and veterans' hospital access into repeat surgical volumes, the pace of new account openings, further international registrations, and the gap between revenue growth and cash burn.

Risks

Revenue is concentrated in a single device, so any setback in Remplir adoption would be felt directly. The peripheral nerve repair market includes larger, better-capitalised competitors, and hospital procurement and reimbursement cycles can be slow.

Orthocell remains unprofitable, and commercial expansion consumes capital even from a solid cash base. Regulatory timelines in new markets sit outside its control.

Conclusion

What could drive Orthocell's next move in September 2026 is less a single event than the credibility of a trend. A record June 2026 quarter, a widening US footprint that now reaches military and veterans' hospitals, and a debt-free Balance Sheet give the company something concrete to build on. Whether that converts into sustained commercial scale remains open, and the outlook may depend on execution and funding discipline.

FAQs

Q: What is the ASX ticker for Orthocell Limited?

A: Orthocell Limited trades under the ticker (ASX:OCC).

Q: Why is Orthocell Limited in focus?

A: The article explains the company developments, operating context and key factors relevant to its current ASX profile.

Q: What should readers monitor next for Orthocell Limited?

A: Readers can monitor company announcements, operational updates and financial disclosures for further developments.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.